EGFR (d752-759)

EGFR · Variant type: unknown

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Dacomitinib	99.9%	0.1%	97.99
2	Canertinib	99.9%	0.1%	96.49
3	Erlotinib	99.7%	0.3%	99.75
4	Neratinib	99.7%	0.3%	93.18
5	Vandetanib	99.6%	0.4%	95.74
6	Osimertinib	99.5%	0.5%	97.24
7	Mobocertinib	99.4%	0.6%	97.22
8	Lazertinib	99.1%	0.9%	97.47
9	Gefitinib	98.5%	1.5%	99.25
10	Ibrutinib	96.7%	3.3%	94.74
11	Afatinib	96.3%	3.7%	98.50
12	Brigatinib	95.0%	5.0%	82.96
13	Lapatinib	93.6%	6.4%	99.25
14	Fostamatinib	87.2%	12.8%	96.74
15	Bosutinib	85.9%	14.1%	87.22
16	Alectinib	83.9%	16.1%	95.49
17	Ponatinib	76.6%	23.4%	78.23
18	Pralsetinib	74.1%	25.9%	93.43
19	Dasatinib	70.6%	29.4%	87.97
20	Gilteritinib	56.2%	43.8%	88.97
21	Pacritinib	54.7%	45.3%	88.64
22	Defactinib	45.1%	54.9%	92.68
23	Ribociclib	13.2%	86.8%	99.25
24	Pazopanib	11.4%	88.6%	97.49
25	Pemigatinib	11.3%	88.7%	98.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Dacomitinib	99.9%	99.8%	+0.1%
Canertinib	99.9%	98.4%	+1.4%
Erlotinib	99.7%	99.4%	+0.3%
Neratinib	99.7%	100.0%	-0.3%
Vandetanib	99.6%	99.3%	+0.3%
Osimertinib	99.5%	99.1%	+0.4%
Mobocertinib	99.4%	100.0%	-0.6%
Lazertinib	99.1%	100.0%	-0.9%
Gefitinib	98.5%	99.9%	-1.4%
Ibrutinib	96.7%	99.3%	-2.6%
Afatinib	96.3%	100.0%	-3.6%
Brigatinib	95.0%	98.5%	-3.5%
Lapatinib	93.6%	99.2%	-5.5%
Fostamatinib	87.2%	97.8%	-10.5%
Bosutinib	85.9%	99.3%	-13.3%
Alectinib	83.9%	—	—
Ponatinib	76.6%	—	—
Pralsetinib	74.1%	99.1%	-25.0%
Dasatinib	70.6%	97.9%	-27.4%
Gilteritinib	56.2%	91.0%	-34.8%
Pacritinib	54.7%	—	—
Defactinib	45.1%	94.6%	-49.4%
Ribociclib	13.2%	—	—
Pazopanib	11.4%	—	—
Pemigatinib	11.3%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 10.3ms